Amgen

News

US immunology biotech Zenas BioPharma files $100m IPO

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 milli

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

Oncology

Paul Burton interview with Jonah Comstock

ASCO 2024 - Paul Burton

For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.

News

Amgen preps Uplizna filing for a second indication

Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, a

News

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi

News

ATS: Amgen, AZ say data backs Tezspire’s role in COPD

Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication fo

US immunology biotech Zenas BioPharma files $100m IPO

Sobi starts rolling FDA filing for chronic gout drug

ASCO 2024 - Paul Burton

Amgen preps Uplizna filing for a second indication

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

ATS: Amgen, AZ say data backs Tezspire’s role in COPD

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Amgen

Editor's Picks